Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region
March 13, 2024 14:13 ET
|
Research and Markets
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution...
Postpartum Depression Market & Epidemiology Research Report 2023-2032: Focus on ZULRESSO (Brexanolone), SAGE-217, and Ganaxolone
January 29, 2024 13:01 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Postpartum Depression - Market Insights, Epidemiology, and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. ...
Nexstim Agrees on a Strategic Investment into a Management Services Organization of a New Jersey Based Clinic Providing Treatments for Depression Patients
January 04, 2024 02:00 ET
|
Nexstim Oyj
Press release, Helsinki, 4 January 2024 at 9 AM (EET) Nexstim Agrees on a Strategic Investment into a Management Services Organization of a New Jersey Based Clinic Providing Treatments for Depression...
TrustPoint Hospital Offers Electroconvulsive Therapy in Inpatient & Outpatient Programs
November 07, 2023 12:11 ET
|
TrustPoint Hospital
MURFREESBORO, Tenn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- TrustPoint Hospital, a top provider of behavioral health treatment in Tennessee, offers electroconvulsive therapy (ECT) for adults who are...
Nexstim’s Quality System and NBS 6 Receive MDR Certification in the EU
May 17, 2023 07:00 ET
|
Nexstim Oyj
Press release, Helsinki, 17 May 2023 at 2 PM (EEST) Nexstim’s Quality System and NBS 6 Receive MDR Certification in the EU Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received...
Nexstim Receives an Order for Two NBT® Systems from Canada
December 14, 2022 03:45 ET
|
Nexstim Oyj
Press release, Helsinki, 14 December 2022 at 10:45 AM (EET) Nexstim Receives an Order for Two NBT® Systems from Canada Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it...
Global Depression Treatment Market Report 2022 to 2032: Featuring AbbVie, Jubilant Generics, Sanis Health, Abbott Laboratories and Aurobindo Pharma Among Others
November 04, 2022 08:46 ET
|
Research and Markets
Dublin, Nov. 04, 2022 (GLOBE NEWSWIRE) -- The "Depression Treatment Market" report has been added to ResearchAndMarkets.com's offering.A recent market study published on the depression treatment...
With 9.0% CAGR, Treatment-Resistant Depression Treatment Market Size Worth USD 2.83 Billion by 2029
November 04, 2022 06:39 ET
|
Fortune Business Insights
Pune, India, Nov. 04, 2022 (GLOBE NEWSWIRE) -- The global treatment-resistant depression treatment market size was valued at USD 1.52 billion in 2021. The market is projected to grow from USD 1.55...
Nexstim Receives an NBT® System Order from Alamo Neurosurgical Institute
October 25, 2022 02:00 ET
|
Nexstim Oyj
Press release, Helsinki, 25 October 2022 at 9 AM (EEST) Nexstim Receives an NBT® System Order from Alamo Neurosurgical Institute Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces...
Global Depression Treatment Therapy Market Report 2022-2028: Selective Serotonin Reuptake Inhibitors (SSRIs) Hold Significant Share
October 10, 2022 06:43 ET
|
Research and Markets
Dublin, Oct. 10, 2022 (GLOBE NEWSWIRE) -- The "Global Depression Treatment Therapy Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering. The global...